Lin Shao-Lee
Known title: CHIEF EXECUTIVE OFFICERCIK: 0001725092
Associated companies
Transaction History
| CUE | ▼ Sell | Open Market | 5,423 | $147K | 8/13/2026 | View on chart |
| CUE | ▼ Sell | Open Market | 2,375 | $67K | 8/13/2026 | View on chart |
| CUE | ▼ Sell | Open Market | 10,460 | $308K | 8/13/2026 | View on chart |
| CUE | ▲ Buy | Option Exercise | 109,179 | $0 | 8/12/2026 | View on chart |
| CUE | ▼ Sell | Open Market | 34,225 | $924K | 8/12/2026 | View on chart |
| CUE | ▼ Sell | Open Market | 5,775 | $160K | 8/12/2026 | View on chart |
| CUE | ▲ Buy | Grant | 327,537 | $0 | 7/9/2026 | View on chart |
| CUE | ▲ Buy | Grant | 327,537 | $0 | 5/3/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Cue Biopharma CUE-221 Meets Phase II Goals for Hives
Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.
Cue Biopharma CUE-221 Meets Phase II Goals for Hives. Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.